CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 30 target
Drug / intervention
Tegafur Gimeracil Oteracil Potassium Capsuledrug
Likely dose
Tegafur Gimeracil Oteracil Potassium Capsule 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01492543
NCT01492543Phase 2Unknown
CompareCT.gov

An Open-label, Single-arm, Multicenter, Phase II Study to Assess the Efficacy and Safety of Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule) as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer

Chinese Academy of Medical Sciences·interventional·Posted Dec 15, 2011·Updated Mar 15, 2013

In Brief

A Phase 2 clinical trial evaluating Tegafur Gimeracil Oteracil Potassium Capsule for Breast Cancer. Targeting 30 participants across 7 sites.

Detailed Summary

The purpose of this study is to assess the effectiveness and safety profile of Aiyi®(Tegafur Gimeracil Oteracil Potassium Capsule, TS-1) as a second line therapy in Chinese female patients with advanced metastatic breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
CollaboratorsPeking University Cancer Hospital & Institute, Beijing Chao Yang Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Tianjin Medical University Cancer Institute and Hospital, Hebei Tumor Hospital

Timeline

Phase 2UnknownOverdue
201220132014201520162017201820192020202120222023202420252026
First PostedDec 15, 2011
Enrollment StartDec 1, 2011
Primary CompletionApr 1, 2014
Study CompletionOct 1, 2014
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 14.5 years ago

Interventions

Tegafur Gimeracil Oteracil Potassium Capsuledrug

Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg\*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,